{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:45:41Z","timestamp":1790595941060,"version":"4.1.0"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-RS-2020-NR049583"],"award-info":[{"award-number":["NRF-RS-2020-NR049583"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF- RS-2024-00397929"],"award-info":[{"award-number":["NRF- RS-2024-00397929"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-RS-2024-00333784"],"award-info":[{"award-number":["NRF-RS-2024-00333784"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12272-025-01566-w","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:08:53Z","timestamp":1757344133000},"page":"858-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis"],"prefix":"10.1007","volume":"48","author":[{"given":"Swapnil P.","family":"Bhujbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-0405","authenticated-orcid":false,"given":"Jung-Mi","family":"Hah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1039\/C9CS00720B","volume":"49","author":"A Abdeldayem","year":"2020","unstructured":"Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT (2020) Advances in covalent kinase inhibitors. Chem Soc Rev 49:2617\u20132687. https:\/\/doi.org\/10.1039\/C9CS00720B","journal-title":"Chem Soc Rev"},{"key":"1566_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jconrel.2024.06.057","volume":"372","author":"P Agarwal","year":"2024","unstructured":"Agarwal P, Reid DL, Amiji M (2024) CNS delivery of targeted protein degraders. JJOCR 372:661\u2013673. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.057","journal-title":"JJOCR"},{"key":"1566_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105090","volume":"160","author":"T Ahmed","year":"2020","unstructured":"Ahmed T, Zulfiqar A, Arguelles S, Rasekhian M, Nabavi SF, Silva AS, Nabavi SM (2020) Map kinase signaling as therapeutic target for neurodegeneration. Pharmacol Res 160:105090. https:\/\/doi.org\/10.1016\/j.phrs.2020.105090","journal-title":"Pharmacol Res"},{"key":"1566_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03833-1","author":"M Ali","year":"2025","unstructured":"Ali M, Erabadda B, Chen Y, Xu Y, Gong K, Liu M, Pichet Binette A, Timsina J, Western D, Yang C (2025) Shared and disease-specific pathways in frontotemporal dementia and Alzheimer\u2019s and Parkinson\u2019s diseases. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03833-1","journal-title":"Nat Med"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"13318","DOI":"10.1021\/jacs.7b05106","volume":"139","author":"DS Allg\u00e4Uer","year":"2017","unstructured":"Allg\u00e4Uer DS, Jangra H, Asahara H, Li Z, Chen Q, Zipse H, Ofial AR, Mayr HJ (2017) Quantification and theoretical analysis of the electrophilicities of Michael acceptors. J Am Chem Soc 139:13318\u201313329. https:\/\/doi.org\/10.1021\/jacs.7b05106","journal-title":"J Am Chem Soc"},{"key":"1566_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, Sattari N, Khorasani M, Farahmand A, Tavakoli S (2024) Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res 55:103043. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103043","journal-title":"Arch Med Res"},{"key":"1566_CR7","doi-asserted-by":"publisher","unstructured":"Amsberg GK-V, Koschmieder S, JO & Therapy (2013) Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. 99\u2013106. https:\/\/doi.org\/10.2147\/OTT.S19901","DOI":"10.2147\/OTT.S19901"},{"key":"1566_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112350","volume":"9","author":"ND Anfinogenova","year":"2020","unstructured":"Anfinogenova ND, Quinn MT, Schepetkin IA, Atochin DN (2020) Alarmins and c-Jun N-terminal kinase (JNK) signaling in neuroinflammation. Cells 9:2350. https:\/\/doi.org\/10.3390\/cells9112350","journal-title":"Cells"},{"key":"1566_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2643943","volume":"2017","author":"AO Ardiles","year":"2017","unstructured":"Ardiles AO, Grabrucker AM, Scholl FG, Rudenko G, Borsello T (2017) Molecular and cellular mechanisms of synaptopathies. Neural Plast 2017:2643943. https:\/\/doi.org\/10.1155\/2017\/2643943","journal-title":"Neural Plast"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","volume":"322","author":"Z Arvanitakis","year":"2019","unstructured":"Arvanitakis Z, Shah RC, Bennett D (2019) Diagnosis and management of dementia. JAMA 322:1589\u20131599. https:\/\/doi.org\/10.1001\/jama.2019.4782","journal-title":"JAMA"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/00498254.2014.990949","volume":"45","author":"C Atsriku","year":"2015","unstructured":"Atsriku C, Hoffmann M, Ye Y, Kumar G, Surapaneni S (2015) Metabolism and disposition of a potent and selective JNK inhibitor [14C] tanzisertib following oral administration to rats, dogs and humans. Xenobiotica 45:428\u2013441. https:\/\/doi.org\/10.3109\/00498254.2014.990949","journal-title":"Xenobiotica"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"Ta Baillie","year":"2016","unstructured":"Baillie Ta (2016) Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl 55:13408\u201313421. https:\/\/doi.org\/10.1002\/anie.201601091","journal-title":"Angew Chem Int Ed Engl"},{"key":"1566_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52573-2","volume":"15","author":"D B\u00e1lint","year":"2024","unstructured":"B\u00e1lint D, P\u00f3ti \u00c1L, Alexa A, Sok P, Albert K, Torda L, F\u00f6ldesi-Nagy D, Cs\u00f3k\u00e1s D, Turczel G, Imre T (2024) Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads. Nat Commun 15:8606. https:\/\/doi.org\/10.1038\/s41467-024-52573-2","journal-title":"Nat Commun"},{"key":"1566_CR14","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1073\/pnas.251194298","volume":"98","author":"BL Bennett","year":"2001","unstructured":"Bennett BL, Sasaki DT, Murray BW, O\u2019Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98:13681\u201313686. https:\/\/doi.org\/10.1073\/pnas.251194298","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1566_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/ph16091295","volume":"16","author":"SP Bhujbal","year":"2023","unstructured":"Bhujbal SP, Hah J (2023) An innovative approach to address neurodegenerative diseases through kinase-targeted therapies: potential for designing covalent inhibitors. Pharmaceuticals 16:1295. https:\/\/doi.org\/10.3390\/ph16091295","journal-title":"Pharmaceuticals"},{"key":"1566_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260853","volume":"16","author":"M Bitew","year":"2021","unstructured":"Bitew M, Desalegn T, Demissie TB, Belayneh A, Endale M, Eswaramoorthy R (2021) Pharmacokinetics and drug-likeness of antidiabetic flavonoids: molecular docking and DFT study. PLoS ONE 16:e0260853. https:\/\/doi.org\/10.1371\/journal.pone.0260853","journal-title":"PLoS ONE"},{"key":"1566_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/mc.20348","volume":"46","author":"AM Bode","year":"2007","unstructured":"Bode AM, Dong ZJ (2007) The functional contrariety of JNK. Mol Carcinog 46:591\u2013598. https:\/\/doi.org\/10.1002\/mc.20348","journal-title":"Mol Carcinog"},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/MMBR.00025-06","volume":"70","author":"MA Bogoyevitch","year":"2006","unstructured":"Bogoyevitch MA, Kobe B (2006) Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. JM & Reviews MB 70:1061\u20131095. https:\/\/doi.org\/10.1128\/MMBR.00025-06","journal-title":"JM & Reviews MB"},{"key":"1566_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2174\/138161207780858384","volume":"13","author":"T Borsello","year":"2007","unstructured":"Borsello T, Forloni G (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm des 13:1875\u20131886. https:\/\/doi.org\/10.2174\/138161207780858384","journal-title":"Curr Pharm des"},{"key":"1566_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070578","volume":"13","author":"C Bouvier","year":"2024","unstructured":"Bouvier C, Lawrence R, Cavallo F, Xolalpa W, Jordan A, Hjerpe R, Rodriguez M (2024) Breaking bad proteins\u2014discovery approaches and the road to clinic for degraders. Cells 13:578. https:\/\/doi.org\/10.3390\/cells13070578","journal-title":"Cells"},{"key":"1566_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40487-015-0010-y","volume":"3","author":"M Breccia","year":"2015","unstructured":"Breccia M, Binotto G (2015) Bosutinib for chronic myeloid leukemia. Rare Cancers and Therapy 3:35\u201346. https:\/\/doi.org\/10.1007\/s40487-015-0010-y","journal-title":"Rare Cancers and Therapy"},{"key":"1566_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1460-9568.2005.03857.x","volume":"21","author":"S Brecht","year":"2005","unstructured":"Brecht S, Kirchhof R, Chromik A, Willesen M, Nicolaus T, Raivich G, Wessig J, Waetzig V, Goetz M, Claussen M (2005) Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 21:363\u2013377. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.03857.x","journal-title":"Eur J Neurosci"},{"key":"1566_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bph.12432","volume":"171","author":"C Bubici","year":"2014","unstructured":"Bubici C, Papa S (2014) JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 171:24\u201337. https:\/\/doi.org\/10.1111\/bph.12432","journal-title":"Br J Pharmacol"},{"key":"1566_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1428\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen P, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, Von Hehn C (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Dis 9:197\u2013210. https:\/\/doi.org\/10.1428\/jpad.2022.30","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1566_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102642","volume":"104","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, Fan Y, Zhang P, Liu H, Han J, Yu Q, Wang X, Wu S, Lu Z (2025) Biomarkers of synaptic degeneration in Alzheimer\u2019s disease. Ageing Res Rev 104:102642. https:\/\/doi.org\/10.1016\/j.arr.2024.102642","journal-title":"Ageing Res Rev"},{"key":"1566_CR26","doi-asserted-by":"publisher","unstructured":"Cheng H, Nair SK, Murray BW, JB & Letters MC (2016) Recent progress on third generation covalent EGFR inhibitors. 26: 1861-1868. https:\/\/doi.org\/10.1016\/j.bmcl.2016.02.067","DOI":"10.1016\/j.bmcl.2016.02.067"},{"key":"1566_CR27","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/biomedicines9101431","volume":"9","author":"H Cho","year":"2021","unstructured":"Cho H, Hah J-M (2021) A Perspective on the development of c-Jun N-terminal kinase inhibitors as therapeutics for Alzheimer\u2019s Disease: investigating Structure through Docking Studies. Biomedicines 9:1431. https:\/\/doi.org\/10.3390\/biomedicines9101431","journal-title":"Biomedicines"},{"key":"1566_CR28","doi-asserted-by":"publisher","unstructured":"Chongtham C, Biswas T, Kumari N, Kar R, Jyotsna, Jayalakshmi S, Pant A, Patil VS & Arimbasseri G, JB (2025) JNK2 pathway in colonocytes enhances gut barrier integrity in response to microbial acetate.2025.01. 24.634634. https:\/\/doi.org\/10.1101\/2025.01.24.634634","DOI":"10.1101\/2025.01.24.634634"},{"key":"1566_CR29","doi-asserted-by":"publisher","unstructured":"Cicenas J, JMK (2015) JNK inhibitors: is there a future? 4. https:\/\/doi.org\/10.4081\/mk.2015.5700","DOI":"10.4081\/mk.2015.5700"},{"key":"1566_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrn3729","volume":"15","author":"ET Coffey","year":"2014","unstructured":"Coffey ET (2014) Nuclear and cytosolic JNK signalling in neurons. Nature Rev Neurosci 15:285\u2013299. https:\/\/doi.org\/10.1038\/nrn3729","journal-title":"Nature Rev Neurosci"},{"key":"1566_CR31","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science1108367","volume":"308","author":"MS Cohen","year":"2005","unstructured":"Cohen MS, Zhang C, Shokat KM, Taunton J (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308:1318\u20131321. https:\/\/doi.org\/10.1126\/science1108367","journal-title":"Science"},{"key":"1566_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"JL Cummings","year":"2019","unstructured":"Cummings JL, Tong G, Ballard CJ (2019) Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options. J Alzheimers Dis 67:779\u2013794. https:\/\/doi.org\/10.3233\/JAD-180766","journal-title":"J Alzheimers Dis"},{"key":"1566_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici G, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen R (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"1566_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","volume":"38","author":"JL Cummings","year":"2024","unstructured":"Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J (2024) Alzheimer\u2019s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs 38:613\u2013624. https:\/\/doi.org\/10.1007\/s40263-024-01103-1","journal-title":"CNS Drugs"},{"key":"1566_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0092-8674(00)00116-1","volume":"103","author":"RJ Davis","year":"2000","unstructured":"Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239\u2013252. https:\/\/doi.org\/10.1016\/s0092-8674(00)00116-1","journal-title":"Cell"},{"key":"1566_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, He J (2024) TGF-\u03b2 signaling in health, disease and therapeutics. Signal Transduct Target Ther 9:61. https:\/\/doi.org\/10.1038\/s41392-024-01764-w","journal-title":"Signal Transduct Target Ther"},{"key":"1566_CR37","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/onc.2008.301","volume":"27","author":"DN Dhanasekaran","year":"2008","unstructured":"Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogene 27:6245\u20136251. https:\/\/doi.org\/10.1038\/onc.2008.301","journal-title":"Oncogene"},{"key":"1566_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Aducanumab: first approval. Drugs 81:1437\u20131443. https:\/\/doi.org\/10.1007\/s40265-021-01569-z","journal-title":"Drugs"},{"key":"1566_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-022-01747-7","volume":"82","author":"DG Di Luca","year":"2022","unstructured":"Di Luca DG, Reyes NGD, Fox SH (2022) Newly approved and investigational drugs for motor symptom control in Parkinson\u2019s disease. Drugs 82:1027\u20131053. https:\/\/doi.org\/10.1007\/s40265-022-01747-7","journal-title":"Drugs"},{"key":"1566_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410416","volume":"12","author":"X Di","year":"2025","unstructured":"Di X, Li Y, Wei J, Li T, Liao B (2025) Targeting fibrosis: from molecular mechanisms to advanced therapies. Adv Sci 12:2410416. https:\/\/doi.org\/10.1002\/advs.202410416","journal-title":"Adv Sci"},{"key":"1566_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00842-z","volume":"20","author":"N Donison","year":"2025","unstructured":"Donison N, Palik J, Volkening K, Strong M (2025) Cellular and molecular mechanisms of pathological tau phosphorylation in traumatic brain injury: implications for chronic traumatic encephalopathy. Mol Neurodegener 20:56. https:\/\/doi.org\/10.1186\/s13024-025-00842-z","journal-title":"Mol Neurodegener"},{"key":"1566_CR42","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1021\/acs.jmedchem.9b00537","volume":"62","author":"X Dou","year":"2019","unstructured":"Dou X, Huang H, Li Y, Jiang L, Wang Y, Jin H, Jiao N, Zhang L, Zhang L, Liu Z (2019) Multistage screening reveals 3-substituted indolin-2-one derivatives as novel and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors: implications to drug discovery for potential treatment of neurodegenerative diseases. J Med Chem 62:6645\u20136664. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00537","journal-title":"J Med Chem"},{"key":"1566_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1471-4159.2007.05101.x","volume":"104","author":"S Eminel","year":"2008","unstructured":"Eminel S, Roemer L, Waetzig V, Herdegen T (2008) C-Jun N-terminal kinases trigger both degeneration and neurite outgrowth in primary hippocampal and cortical neurons. J Neurochem 104:957\u2013969. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05101.x","journal-title":"J Neurochem"},{"key":"1566_CR44","volume-title":"Seminars in cell & developmental biology","author":"KW Finnson","year":"2020","unstructured":"Finnson KW, Almadani Y, Philip A (2020) Non-canonical (non-SMAD2\/3) TGF-\u03b2 signaling in fibrosis: mechanisms and targets. Seminars in cell & developmental biology. Elsevier, Amsterdam"},{"key":"1566_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.abb.2005.04.013","volume":"438","author":"M Fricker","year":"2005","unstructured":"Fricker M, Lograsso P, Ellis S, Wilkie N, Hunt P, Pollack S (2005) Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK-and p38-selective inhibitors. Arch Biochem Biophys 438:195\u2013205. https:\/\/doi.org\/10.1016\/j.abb.2005.04.013","journal-title":"Arch Biochem Biophys"},{"key":"1566_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107245","volume":"205","author":"I Fuster-Mart\u00ednez","year":"2024","unstructured":"Fuster-Mart\u00ednez I, Calatayud S (2024) The current landscape of antifibrotic therapy across different organs: a systematic approach. Pharmacol Res 205:107245","journal-title":"Pharmacol Res"},{"key":"1566_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082598","volume":"14","author":"S Galli","year":"2025","unstructured":"Galli S, Pacilio P, Bianchini E, Alborghetti M, De Carolis L, Lombardo P, Garramone F, Salvetti M, Rinaldi D (2025) The role of MAO-B inhibitors in fatigue in Parkinson\u2019s disease: a narrative review. J Clin Med 14:2598","journal-title":"J Clin Med"},{"issue":"6","key":"1566_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.pupt.2013.03.006","volume":"26","author":"Y Gao","year":"2013","unstructured":"Gao Y, Lu J, Zhang Y, Chen Y, Gu Z, Jiang X (2013) Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21. Pulm Pharmacol Ther 26(6):649\u2013654","journal-title":"Pulm Pharmacol Ther"},{"key":"1566_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1503\/jpn.140062","volume":"40","author":"S Gourmaud","year":"2015","unstructured":"Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, Laplanche J-L, Meurs EF, Mouton-Liger F, Hugon J (2015) Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. J Psychiatry Neurosci 40:151\u2013161. https:\/\/doi.org\/10.1503\/jpn.140062","journal-title":"J Psychiatry Neurosci"},{"key":"1566_CR50","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1016\/j.bmcl.2005.07.076","volume":"15","author":"PP Graczyk","year":"2005","unstructured":"Graczyk PP, Khan A, Bhatia GS, Palmer V, Medland D, Numata H, Oinuma H, Catchick J, Dunne A, Ellis M (2005) The neuroprotective action of JNK3 inhibitors based on the 6, 7-dihydro-5H-pyrrolo [1, 2-a] imidazole scaffold. Bioorganic Med Chem Lett. 15:4666\u20134670","journal-title":"Bioorganic Med Chem Lett."},{"key":"1566_CR51","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40263-015-0287-2","volume":"29","author":"SL Greig","year":"2015","unstructured":"Greig SL (2015) Memantine ER\/donepezil: a review in Alzheimer\u2019s disease. CNS Drugs 29:963\u2013970. https:\/\/doi.org\/10.1007\/s40263-015-0287-2","journal-title":"CNS Drugs"},{"key":"1566_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00829","author":"K Grynberg","year":"2017","unstructured":"Grynberg K, Ma FY, Nikolic-Paterson D (2017) The JNK signaling pathway in renal fibrosis. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2017.00829","journal-title":"Front Physiol"},{"key":"1566_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.brainres.2006.03.086","volume":"1092","author":"Q-H Guan","year":"2006","unstructured":"Guan Q-H, Pei D-S, Liu X-M, Wang X-T, Xu T-L, Zhang G-Y (2006) Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis. Brain Res 1092:36\u201346. https:\/\/doi.org\/10.1016\/j.brainres.2006.03.086","journal-title":"Brain Res"},{"key":"1566_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and disease. Acta Neuropathol 133:665\u2013704. https:\/\/doi.org\/10.1007\/s00401-017-1707-9","journal-title":"Acta Neuropathol"},{"key":"1566_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1831","volume":"10","author":"J Guo","year":"2020","unstructured":"Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R (2020) Memantine, donepezil, or combination therapy\u2014What is the best therapy for Alzheimer\u2019s disease? A network meta-analysis. J Behav 10:e01831. https:\/\/doi.org\/10.1002\/brb3.1831","journal-title":"J Behav"},{"key":"1566_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.108044","volume":"154","author":"Y Guo","year":"2025","unstructured":"Guo Y, Liu F, Chi M, Qian H, Zhang Y, Yuan Y, Hou S, Chen X, Ma L (2025) Design and synthesis of JNK1-targeted PROTACs and research on the activity. Bioorg Chem 154:108044. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108044","journal-title":"Bioorg Chem"},{"key":"1566_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175629","author":"H Hao","year":"2023","unstructured":"Hao H, Yuan T, Li Z, Zhang C, Liu J, Liang G, Feng L, Pan Y (2023) Curcumin analogue C66 ameliorates mouse cardiac dysfunction and structural disorders after acute myocardial infarction via suppressing JNK activation. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175629","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"1566_CR58","doi-asserted-by":"publisher","first-page":"00431","DOI":"10.1016\/j.jare.2024.09.029","volume":"S2090\u20131232","author":"M Hao","year":"2024","unstructured":"Hao M, Lu Y, Yao Z, Wang P, Chen Z, Zhou L, Yang Q, Sang X, Wang K, Cao G (2024) The role of JNK signaling pathway in organ fibrosis. J Adv Res S2090\u20131232(24):00431\u201300434. https:\/\/doi.org\/10.1016\/j.jare.2024.09.029","journal-title":"J Adv Res"},{"key":"1566_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249677","volume":"21","author":"SC Hepp Rehfeldt","year":"2020","unstructured":"Hepp Rehfeldt SC, Majolo F, Goettert MI, Laufer SJ (2020) C-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer\u2019s diseases. Int J Mol Sci 21:9677. https:\/\/doi.org\/10.3390\/ijms21249677","journal-title":"Int J Mol Sci"},{"key":"1566_CR60","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","volume":"67","author":"L Hillebrand","year":"2024","unstructured":"Hillebrand L, Liang XJ, Serafim RA, Gehringer MJ (2024) Emerging and re-emerging warheads for targeted covalent inhibitors: an update. J Med Chem 67:7668\u20137758. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01825","journal-title":"J Med Chem"},{"key":"1566_CR61","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph16020264","volume":"16","author":"BS Hoffelner","year":"2023","unstructured":"Hoffelner BS, Andreev S, Plank N, Koch P (2023) Photocaging of pyridinylimidazole-based covalent JNK3 inhibitors affords spatiotemporal control of the binding affinity in live cells. Pharmaceuticals 16:264. https:\/\/doi.org\/10.3390\/ph16020264","journal-title":"Pharmaceuticals"},{"key":"1566_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1152\/physiol.00033.2018","volume":"34","author":"JC Horowitz","year":"2019","unstructured":"Horowitz JC, Thannickal VJ (2019) Mechanisms for the resolution of organ fibrosis. Physiology (Bethesda) 34:43\u201355. https:\/\/doi.org\/10.1152\/physiol.00033.2018","journal-title":"Physiology (Bethesda)"},{"key":"1566_CR63","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, Mcshane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 366:893\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa1106668","journal-title":"N Engl J Med"},{"key":"1566_CR64","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41386-024-01943-x","volume":"50","author":"O Howes","year":"2025","unstructured":"Howes O, Marcinkowska J, Turkheimer FE, Carr R (2025) Synaptic changes in psychiatric and neurological disorders: state-of-the-art of in vivo imaging. Neuropsychopharmacology 50:164\u2013183","journal-title":"Neuropsychopharmacology"},{"key":"1566_CR65","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.expneurol.2015.10.010","volume":"277","author":"Q Huang","year":"2016","unstructured":"Huang Q, Du X, He X, Yu Q, Hu K, Breitwieser W, Shen Q, Ma S, Li M, JEN (2016) JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson\u2019s disease. Exp Neurol 277:296\u2013304","journal-title":"Exp Neurol"},{"key":"1566_CR66","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1039\/D4TB00737A","volume":"12","author":"S Huang","year":"2024","unstructured":"Huang S, Lu H, Chen J, Jiang C, Jiang G, Maduraiveeran G, Pan Y, Liu J, Deng L-E (2024) Advances in drug delivery-based therapeutic strategies for renal fibrosis treatment. J Mater Chem B 12:6532\u20136549","journal-title":"J Mater Chem B"},{"key":"1566_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s40001-024-01915-3","volume":"29","author":"I Iqbal","year":"2024","unstructured":"Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B, Shahzad H, Sharifi-Rad J, Mubarak MS (2024) Alzheimer\u2019s disease and drug delivery across the blood\u2013brain barrier: approaches and challenges. Eur J Med Res 29:313. https:\/\/doi.org\/10.1186\/s40001-024-01915-3","journal-title":"Eur J Med Res"},{"key":"1566_CR68","volume":"29","author":"J Irma","year":"2025","unstructured":"Irma J, Kartasasmita AS, Kartiwa A, Irfani I, Rizki SA, Onasis SJ (2025) From growth factors to structure: PDGF and TGF-\u03b2 in Granulation Tissue Formation. Lit Rev 29:e70374","journal-title":"Lit Rev"},{"key":"1566_CR69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/mol.105.017483","volume":"69","author":"M Jinnin","year":"2006","unstructured":"Jinnin M, Ihn H, Tamaki K (2006) Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-\u03b21-induced extracellular matrix expression. Mol Pharmacol 69:597\u2013607","journal-title":"Mol Pharmacol"},{"key":"1566_CR70","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.2174\/13895575112091330","volume":"12","author":"HM Johansson","year":"2012","unstructured":"Johansson HM (2012) Reversible Michael additions: covalent inhibitors and prodrugs. Mini Rev Med Chem 12:1330\u20131344. https:\/\/doi.org\/10.2174\/13895575112091330","journal-title":"Mini Rev Med Chem"},{"key":"1566_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011084","volume":"22","author":"J Jun","year":"2021","unstructured":"Jun J, Baek J, Yang S, Moon H, Kim H, Cho HW, Hah J-M (2021) Discovery of a potent and selective JNK3 inhibitor with neuroprotective effect against amyloid-induced neurotoxicity in primary rat neurons. Int J Mol Sci 22:11084. https:\/\/doi.org\/10.3390\/ijms222011084","journal-title":"Int J Mol Sci"},{"key":"1566_CR72","doi-asserted-by":"publisher","first-page":"6372","DOI":"10.1021\/acs.jmedchem.3c00393","volume":"66","author":"J Jun","year":"2023","unstructured":"Jun J, Moon H, Yang S, Lee J, Baek J, Kim H, Cho H, Hwang K, Ahn S, Kim YJ (2023a) Carbamate JNK3 inhibitors show promise as effective treatments for Alzheimer\u2019s disease. In vivo studies on mouse models. J Med Chem 66:6372\u20136390. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00393","journal-title":"J Med Chem"},{"key":"1566_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114894","volume":"245","author":"J Jun","year":"2023","unstructured":"Jun J, Yang S, Lee J, Moon H, Kim J, Jung H, Im D, Oh Y, Jang M, Cho HJ (2023b) Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 245:114894. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114894","journal-title":"Eur J Med Chem"},{"key":"1566_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60123-7","volume":"16","author":"Z Kang","year":"2025","unstructured":"Kang Z, Yang M, Liu Y, Gui Y, Dong Y, Zhou H, Zhang Z, Li M, Fan H, Li Z (2025) Myocardial mitochondrial antiviral signaling protein promotes heart ischemia-reperfusion injury via RIG-I signaling in mice. Nat Commun 16:5101","journal-title":"Nat Commun"},{"key":"1566_CR75","unstructured":"Karunarathna I, Wijepala J, Rodrigo P, Ranasinghe S, Senanayaka S, Jayawardana A, Fernando C, Vidanagama U, Ekanayake U & Hapuarachchi T Clinical Implications of Dopamine Agonists: Adverse Effects, indications and Monitoring."},{"key":"1566_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116041","volume":"22","author":"Y Kasuya","year":"2021","unstructured":"Kasuya Y, Kim J-D, Hatano M, Tatsumi K, Matsuda S (2021) Pathophysiological roles of stress-activated protein kinases in pulmonary fibrosis. Int J Mol Sci 22:6041","journal-title":"Int J Mol Sci"},{"key":"1566_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117209","volume":"285","author":"H Kim","year":"2025","unstructured":"Kim H, Park H, Jun J, Moon J, Oh J, Bhujbal SP, Hah J-M (2025) Targeting JNK3 for Alzheimer\u2019s disease: design and synthesis of novel inhibitors with aryl group diversity utilizing wide pocket. Eur J Med Chem 285:117209. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117209","journal-title":"Eur J Med Chem"},{"key":"1566_CR78","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S466829","author":"T Klett","year":"2024","unstructured":"Klett T, Schwer M, Ernst LN, Engelhardt MU, Jaag SJ, Masberg B, Knappe C, L\u00e4mmerhofer M, Gehringer M, Boeckler FM (2024) Evaluation of a covalent library of diverse warheads (CovLib) binding to JNK3, USP7, or p53. Drug des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S466829","journal-title":"Drug des Devel Ther"},{"key":"1566_CR79","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/B978-0-12-819410-2.00027-8","volume":"184","author":"G Koch","year":"2022","unstructured":"Koch G, Spampinato D (2022) Alzheimer disease and neuroplasticity. Handb Clin Neurol 184:473\u2013479. https:\/\/doi.org\/10.1016\/B978-0-12-819410-2.00027-8","journal-title":"Handb Clin Neurol"},{"key":"1566_CR80","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.bmcl.2011.12.027","volume":"22","author":"VP Krenitsky","year":"2012","unstructured":"Krenitsky VP, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R, Albers R, Hegde S, D\u2019sidocky N, Sapienza J (2012) Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorganic Med Chem Lett 22:1433\u20131438","journal-title":"Bioorganic Med Chem Lett"},{"key":"1566_CR81","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/s0896-6273(00)80727-8","volume":"22","author":"K-Y Kuan","year":"1999","unstructured":"Kuan K-Y, Yang DD, Roy DRS, Davis RJ, Rakic P, Flavell RA (1999) The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22:667\u2013676. https:\/\/doi.org\/10.1016\/s0896-6273(00)80727-8","journal-title":"Neuron"},{"key":"1566_CR82","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00044-022-02953-4","volume":"31","author":"H Kumar","year":"2022","unstructured":"Kumar H, Goyal A, Kumar N, Garg P (2022) Design, synthesis, and biological evaluation of pyrazolo-benzothiazole derivatives as a potential therapeutic agent for the treatment of Alzheimer\u2019s disease. Med Chem Res 31:1931\u20131947. https:\/\/doi.org\/10.1007\/s00044-022-02953-4","journal-title":"Med Chem Res"},{"key":"1566_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM (2018) Alzheimer\u2019s disease. Eur J Neurol 25:59\u201370. https:\/\/doi.org\/10.1111\/ene.13439","journal-title":"Eur J Neurol"},{"key":"1566_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02476-20.10.1128\/AAC.02476-20","author":"A Lee","year":"2021","unstructured":"Lee A, Wang N, Carter CL, Zimmerman M, Dartois V, Shaw KJ, Perlin DS, Zhao Y (2021) Therapeutic potential of fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02476-20.10.1128\/AAC.02476-20","journal-title":"Antimicrob Agents Chemother"},{"key":"1566_CR85","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1073\/pnas.0438011100","volume":"100","author":"K Lei","year":"2003","unstructured":"Lei K, Davis R (2003) JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 100:2432\u20132437","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1566_CR86","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM (2022) PROTACs: past, present and future. Chem Soc Rev 51:5214\u20135236","journal-title":"Chem Soc Rev"},{"key":"1566_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100751","volume":"13","author":"Z Li","year":"2020","unstructured":"Li Z, Sun C, Tao S, Osunkoya AO, Arnold RS, Petros JA, Zu X, Moreno CS (2020) The JNK inhibitor AS602801 synergizes with enzalutamide to kill prostate cancer cells in vitro and in vivo and inhibit androgen receptor expression. Transl Oncol 13:100751","journal-title":"Transl Oncol"},{"key":"1566_CR88","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2174\/0929867327666200210144114","volume":"28","author":"G Li","year":"2021","unstructured":"Li G, Qi W, Li X, Zhao J, Luo M, Chen J (2021) Recent advances in c-Jun N-terminal kinase (JNK) inhibitors. Curr Med Chem 28:607\u2013627","journal-title":"Curr Med Chem"},{"key":"1566_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1284214","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y-J, Zhu Z-Q (2023) To re-examine the intersection of microglial activation and neuroinflammation in neurodegenerative diseases from the perspective of pyroptosis. Front Aging Neurosci 15:1284214","journal-title":"Front Aging Neurosci"},{"key":"1566_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095610","volume":"15","author":"M Li","year":"2025","unstructured":"Li M, Ye X, Huang Z, Ye L, Chen C (2025) Global burden of Parkinson\u2019s disease from 1990 to 2021: a population-based study. BMJ Open 15:e095610","journal-title":"BMJ Open"},{"key":"1566_CR91","doi-asserted-by":"crossref","unstructured":"Liang G-Q, Mu W & Jiang C, BJH (2024) Baicalein improves renal interstitial fibrosis by inhibiting the ferroptosis in vivo and in vitro. 10.","DOI":"10.1016\/j.heliyon.2024.e28954"},{"key":"1566_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0421-9","volume":"25","author":"C-H Lin","year":"2018","unstructured":"Lin C-H, Shih C-H, Lin Y-C, Yang Y-L, Chen B-C (2018) MEKK1, JNK, and SMAD3 mediate CXCL12-stimulated connective tissue growth factor expression in human lung fibroblasts. J Biomed Sci 25:19","journal-title":"J Biomed Sci"},{"key":"1566_CR93","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1055\/a-2483-0107","volume":"125","author":"TL Lindahl","year":"2025","unstructured":"Lindahl TL, Kumar AP, Hallstr\u00f6m T, Al-Hashimi A, Du Rietz A, Arlaman E, Uvdal K, Macwan AS (2025) Dabigatran attenuates the binding of thrombin to platelets\u2014a novel mechanism of action. Thromb Haemost 125:747\u2013756","journal-title":"Thromb Haemost"},{"key":"1566_CR94","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio799","volume":"2","author":"Y Liu","year":"2006","unstructured":"Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358\u2013364. https:\/\/doi.org\/10.1038\/nchembio799","journal-title":"Nat Chem Biol"},{"key":"1566_CR95","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1021\/acs.jmedchem.1c01186","volume":"65","author":"R Liu","year":"2021","unstructured":"Liu R, Zhan S, Che Y, Shen J (2021) Reactivities of the front pocket N-terminal cap cysteines in human kinases. J Med Chem 65:1525\u20131535. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01186","journal-title":"J Med Chem"},{"key":"1566_CR96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","volume":"3","author":"Z Liu","year":"2022","unstructured":"Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y (2022) An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed 3:46. https:\/\/doi.org\/10.1186\/s43556-022-00112-0","journal-title":"Mol Biomed"},{"key":"1566_CR97","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/138955708784912120","volume":"8","author":"P Lograsso","year":"2008","unstructured":"Lograsso P, Kamenecka T (2008) Inhibitors of c-jun-N-terminal kinase (JNK). Mini Rev Med Chem 8:755\u2013766. https:\/\/doi.org\/10.2174\/138955708784912120","journal-title":"Mini Rev Med Chem"},{"key":"1566_CR98","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/104012371803000307","volume":"30","author":"S Lu","year":"2018","unstructured":"Lu S, Nasrallah Ha (2018) The use of memantine in neuropsychiatric disorders: an overview. Ann Clin Psychiatry 30:234\u2013248","journal-title":"Ann Clin Psychiatry"},{"key":"1566_CR99","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1021\/acs.jmedchem.2c01834","volume":"66","author":"W Lu","year":"2023","unstructured":"Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L, Ficarro SB, Meyer CJ, Sinha D, You IJ (2023) Development of a covalent inhibitor of c-Jun N-terminal protein kinase (JNK) 2\/3 with selectivity over JNK1. J Med Chem 66:3356\u20133371. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01834","journal-title":"J Med Chem"},{"key":"1566_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101191","volume":"92","author":"I Lurje","year":"2023","unstructured":"Lurje I, Gaisa NT, Weiskirchen R, Tacke F (2023) Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol Aspects Med 92:101191","journal-title":"Mol Aspects Med"},{"key":"1566_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1535555","volume":"16","author":"J Lv","year":"2025","unstructured":"Lv J, Song X, Luo Z, Huang D, Xiao L, Zou K (2025) Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases. Front Pharmacol 16:1535555","journal-title":"Front Pharmacol"},{"key":"1566_CR102","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1681\/ASN.2006060604","volume":"18","author":"FY Ma","year":"2007","unstructured":"Ma FY, Flanc RS, Tesch GH, Han Y, Atkins RC, Bennett BL, Friedman GC, Fan J-H, Nikolic-Paterson DJ (2007) A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 18:472\u2013484","journal-title":"J Am Soc Nephrol"},{"key":"1566_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/cells13010079","volume":"13","author":"Y Ma","year":"2023","unstructured":"Ma Y, Wang W, Liu S, Qiao X, Xing Y, Zhou Q, Zhang Z (2023) Epigenetic regulation of neuroinflammation in Alzheimer\u2019s disease. Cells 13:79. https:\/\/doi.org\/10.3390\/cells13010079","journal-title":"Cells"},{"key":"1566_CR104","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrd1132","volume":"2","author":"AM Manning","year":"2003","unstructured":"Manning AM, Davis RJ (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2:554\u2013565. https:\/\/doi.org\/10.1038\/nrd1132","journal-title":"Nat Rev Drug Discov"},{"key":"1566_CR105","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/rccm.202310-1907OC","volume":"210","author":"WL Mattos Mattos","year":"2024","unstructured":"Mattos Mattos WL, Khalil N, Spencer LG, Bonella F, Folz RJ, Rolf JD, Mogulkoc N, Lancaster LH, Jenkins RG, Lynch D (2024) Phase 2, double-blind, placebo-controlled trial of a c-Jun N-terminal kinase inhibitor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 210:435\u2013443. https:\/\/doi.org\/10.1164\/rccm.202310-1907OC","journal-title":"Am J Respir Crit Care Med"},{"key":"1566_CR106","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JPD-202128","volume":"10","author":"K McFarthing","year":"2020","unstructured":"McFarthing K, Buff S, Rafaloff G, Dominey T, Wyse R (2020) Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2020. J Parkinsons Dis 10:757\u2013774. https:\/\/doi.org\/10.3233\/JPD-202128","journal-title":"J Parkinsons Dis"},{"key":"1566_CR107","doi-asserted-by":"crossref","unstructured":"Mcgregor ER, Lasky DJ, Rippentrop OJ, Clark JP, Wright S, Jones MV & Anderson RM, JCB (2025) Reversal of neuronal tau pathology via adiponectin receptor activation. 8:8.","DOI":"10.1038\/s42003-024-07391-z"},{"key":"1566_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2025.04.005","author":"CD Mckenney","year":"2025","unstructured":"Mckenney CD, Regot S (2025) Cell cycle regulation by the ribotoxic stress response. Trends Cell Biol. https:\/\/doi.org\/10.1016\/j.tcb.2025.04.005","journal-title":"Trends Cell Biol"},{"issue":"3","key":"1566_CR109","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s12031-010-9454-6","volume":"43","author":"S Mehan","year":"2011","unstructured":"Mehan S, Meena H, Sharma D, Sankhla RJ (2011) JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer\u2019s and various neurodegenerative abnormalities. J Mol Neurosci 43(3):376\u2013390","journal-title":"J Mol Neurosci"},{"key":"1566_CR110","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.chembiol.2014.09.007","volume":"21","author":"A Messoussi","year":"2014","unstructured":"Messoussi A, Feneyrolles C, Bros A, Deroide A, Dayde-Cazals B, Cheve G, Van Hijfte N, Fauvel B, Bougrin K, Yasri A (2014) Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. Chem Biol 21:1433\u20131443","journal-title":"Chem Biol"},{"key":"1566_CR111","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMoa2100708","volume":"385","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Wessels AM, Sims JR (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 385:667\u2013667. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"1566_CR112","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41598-018-27867-3Mintun","volume":"385","author":"P Mishra","year":"2018","unstructured":"Mishra P, G\u00fcnther S (2018) New insights into the structural dynamics of the kinase Wessels AM & Sims JR, (2021) Donanemab in Early Alzheimer\u2019s Disease. Sci Rep 385:667\u2013667. https:\/\/doi.org\/10.1038\/s41598-018-27867-3Mintun","journal-title":"Sci Rep"},{"key":"1566_CR113","doi-asserted-by":"publisher","first-page":"103940","DOI":"10.1016\/j.etap.2022.103940","volume":"95","author":"MZ Mohamed","year":"2022","unstructured":"Mohamed MZ, El Baky MFA, Ali ME, Hafez HM (2022) Aprepitant exerts anti-fibrotic effect via inhibition of TGF-\u03b2\/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats. Environ Toxicol Pharmacol 95:103940","journal-title":"Environ Toxicol Pharmacol"},{"key":"1566_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/cells14120896","author":"NA Muraleva","year":"2025","unstructured":"Muraleva NA, Tikhonov DI, Zhdankina AA, Plotnikov MB, Khlebnikov AI, Logvinov SV, Kolosova NG (2025) Alterations of JNK signaling pathway activity in the rat retina: effects of age, age-related macular degeneration-like pathology, and a JNK inhibitor (IQ-1S). Cells. https:\/\/doi.org\/10.3390\/cells14120896","journal-title":"Cells"},{"key":"1566_CR115","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3390\/cells9102190","volume":"9","author":"CA Musi","year":"2020","unstructured":"Musi CA, Agr\u00f2 G, Santarella F, Iervasi E, Borsello T (2020) JNK3 as therapeutic target and biomarker in neurodegenerative and neurodevelopmental brain diseases. Cells 9:2190. https:\/\/doi.org\/10.3390\/cells9102190","journal-title":"Cells"},{"key":"1566_CR116","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/acs.jmedchem.6b01180","volume":"60","author":"F Muth","year":"2017","unstructured":"Muth F, El-Gokha A, Ansideri F, Eitel M, D\u00f6Ring E, Sievers-Engler A, Lange A, Boeckler FM, L\u00e4Mmerhofer M, Koch PJ (2017) Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3. J Med Chem 60:594\u2013607. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01180","journal-title":"J Med Chem"},{"key":"1566_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.793507","volume":"8","author":"HA Mutsaers","year":"2021","unstructured":"Mutsaers HA, N\u00f8rregaard R, Olinga P (2021) Organ fibrosis: pathogenesis, biomarkers and therapeutic targets. Front Media 8:793507. https:\/\/doi.org\/10.3389\/fmed.2021.793507","journal-title":"Front Media"},{"key":"1566_CR118","doi-asserted-by":"publisher","first-page":"18193","DOI":"10.1021\/acs.jmedchem.1c01716","volume":"64","author":"MA Nagy","year":"2021","unstructured":"Nagy MA, Hilgraf R, Mortensen DS, Elsner J, Norris S, Tikhe J, Yoon W, Paisner D, Delgado M, Erdman P (2021) Discovery of the c-Jun N-terminal kinase inhibitor CC-90001. J Med Chem 64:18193\u201318208","journal-title":"J Med Chem"},{"key":"1566_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182923","author":"S Namba","year":"2017","unstructured":"Namba S, Nakano R, Kitanaka T, Kitanaka N, Nakayama T, Sugiya H (2017) ERK2 and JNK1 contribute to TNF-\u03b1-induced IL-8 expression in synovial fibroblasts. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0182923","journal-title":"PLoS ONE"},{"key":"1566_CR120","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/187152008785914770","volume":"8","author":"TL Nguyen","year":"2008","unstructured":"Nguyen TL (2008) Targeting RSK: an overview of small molecule inhibitors. Anticancer Agents Med Chem 8:710\u2013716. https:\/\/doi.org\/10.2174\/187152008785914770","journal-title":"Anticancer Agents Med Chem"},{"key":"1566_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01535-7","volume":"21","author":"C Nieto-Jim\u00e9nez","year":"2022","unstructured":"Nieto-Jim\u00e9nez C, Morafraile EC, Alonso-Moreno C, Oca\u00f1a A (2022) Clinical considerations for the design of PROTACs in cancer. Mol Cancer 21:67","journal-title":"Mol Cancer"},{"key":"1566_CR122","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00125-020-05327-w","volume":"64","author":"R Nogueiras","year":"2021","unstructured":"Nogueiras R, Sabio G (2021) Brain JNK and metabolic disease. Diabetologia 64:265\u2013274","journal-title":"Diabetologia"},{"key":"1566_CR123","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8395","volume":"7","author":"M Okada","year":"2016","unstructured":"Okada M, Kuramoto K, Takeda H, Watarai H, Sakaki H, Seino S, Seino M, Suzuki S, Kitanaka C, JO (2016) The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo. Oncotarget 7:27021","journal-title":"Oncotarget"},{"key":"1566_CR124","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10349-x","volume":"52","author":"MO Oyovwi","year":"2025","unstructured":"Oyovwi MO, Udi OA, Atere AD, Joseph GU, Ogbutor UG (2025) Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy. Mol Biol Rep 52:240","journal-title":"Mol Biol Rep"},{"key":"1566_CR125","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1933719115600553","volume":"23","author":"SS Palmer","year":"2016","unstructured":"Palmer SS, Altan M, Denis D, Tos EG, Gotteland J-P, Osteen KG, Bruner-Tran KL, Nataraja SG (2016) Bentamapimod (JNK inhibitor AS602801) induces regression of endometriotic lesions in animal models. Reprod Sci 23:11\u201323. https:\/\/doi.org\/10.1177\/1933719115600553","journal-title":"Reprod Sci"},{"key":"1566_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129569","volume":"1864","author":"G Pandey","year":"2020","unstructured":"Pandey G, Morla S, Kumar S, Ramakrishnan V (2020) Modulation of tau protein aggregation using \u2018Trojan\u2019sequences. Biochim Biophys Acta Gen Subj 1864:129569. https:\/\/doi.org\/10.1016\/j.bbagen.2020.129569","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"1566_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.142179","volume":"1339","author":"H Park","year":"2025","unstructured":"Park H, Feng Y (2025) Structural study of selectivity mechanisms for JNK3 and p38\u03b1 with indazole scaffold probing compounds. J Mol Struc 1339:142179","journal-title":"J Mol Struc"},{"key":"1566_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/srep08047","volume":"5","author":"H Park","year":"2015","unstructured":"Park H, Iqbal S, Hernandez P, Mora R, Zheng K, Feng Y, Lograsso P (2015) Structural basis and biological consequences for JNK2\/3 isoform selective aminopyrazoles. Sci Rep 5:8047. https:\/\/doi.org\/10.1038\/srep08047","journal-title":"Sci Rep"},{"key":"1566_CR129","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17460441.2022.2034783","volume":"17","author":"N P\u00e9czka","year":"2022","unstructured":"P\u00e9czka N, Orgov\u00e1n Z, \u00c1br\u00e1nyi-Balogh P, Keser\u0171 GM (2022) Electrophilic warheads in covalent drug discovery: an overview. Expert Opin Drug Discov 17:413\u2013422. https:\/\/doi.org\/10.1080\/17460441.2022.2034783","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"1566_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X (2022) Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer 21(1):104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x","journal-title":"Mol Cancer"},{"key":"1566_CR131","doi-asserted-by":"publisher","first-page":"15200","DOI":"10.1002\/anie.201707630","volume":"56","author":"J Pettinger","year":"2017","unstructured":"Pettinger J, Jones K, Cheeseman MD (2017) Lysine-targeting covalent inhibitors. Angew Chem Int Ed Engl 56:15200\u201315209. https:\/\/doi.org\/10.1002\/anie.201707630","journal-title":"Angew Chem Int Ed Engl"},{"key":"1566_CR132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025242118","volume":"118","author":"P Piccolo","year":"2021","unstructured":"Piccolo P, Ferriero R, Barbato A, Attanasio S, Monti M, Perna C, Borel F, Annunziata P, Carissimo A, De Cegli R (2021) Up-regulation of miR-34b\/c by JNK and FOXO3 protects from liver fibrosis. Proc Natl Acad Sci U S A 118:e2025242118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1566_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001060","volume":"9","author":"Z Popmihajlov","year":"2022","unstructured":"Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S (2022) CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respir Res 9:e001060","journal-title":"BMJ Open Respir Res"},{"key":"1566_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106090","volume":"128","author":"P Qin","year":"2022","unstructured":"Qin P, Ran Y, Liu Y, Wei C, Luan X, Niu H, Peng J, Sun J, Wu J (2022) Recent advances of small molecule JNK3 inhibitors for Alzheimer\u2019s disease. Bioorg Chem 128:106090. https:\/\/doi.org\/10.1016\/j.bioorg.2022.106090","journal-title":"Bioorg Chem"},{"key":"1566_CR135","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/cells11121885","volume":"11","author":"Y Rajesh","year":"2022","unstructured":"Rajesh Y, Kanneganti T-D (2022) Innate immune cell death in neuroinflammation and Alzheimer\u2019s disease. Cells 11:1885. https:\/\/doi.org\/10.3390\/cells11121885","journal-title":"Cells"},{"key":"1566_CR136","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01308","author":"YS Raouf","year":"2024","unstructured":"Raouf YS (2024) Covalent inhibitors: to infinity and beyond. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01308","journal-title":"J Med Chem"},{"key":"1566_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci 16:970925","journal-title":"Front Neurosci"},{"key":"1566_CR138","doi-asserted-by":"publisher","first-page":"20178","DOI":"10.1002\/anie.202103767","volume":"60","author":"M Reynders","year":"2021","unstructured":"Reynders M, Chaikuad A, Berger BT, Bauer K, Koch P, Laufer S, Knapp S, Trauner D (2021) Controlling the covalent reactivity of a kinase inhibitor with light. Angew Chem Int Ed Engl 60:20178\u201320183. https:\/\/doi.org\/10.1002\/anie.202103767","journal-title":"Angew Chem Int Ed Engl"},{"key":"1566_CR139","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02893-4","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, L\u00f6schmann P-A, Sian-Hulsmann J, Jost WH, M\u00fcller T, Dijkstra J (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm"},{"key":"1566_CR140","doi-asserted-by":"crossref","unstructured":"Sahithi LS, Nuthalapati P, Hussain MF, Nagabhishek SN, Umeza B, Santoshi RD, Afzal KA & Ghanta MK, JCRIO (2025) Efficacy and Safety of JNK Inhibitors in Cancer Therapy. 30.","DOI":"10.1615\/CritRevOncog.2025060497"},{"key":"1566_CR141","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, Cummings J, Van Der Flier WM (2021) Alzheimer\u2019s disease. Lancet 397:1577\u20131590. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4","journal-title":"Lancet"},{"key":"1566_CR142","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"1566_CR143","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12026-022-09267-y","volume":"70","author":"N Shi","year":"2022","unstructured":"Shi N, Wang Z, Zhu H, Liu W, Zhao M, Jiang X, Zhao J, Ren C, Zhang Y, Luo L (2022) Research progress on drugs targeting the TGF-\u03b2 signaling pathway in fibrotic diseases. Immunol Res 70:276\u2013288. https:\/\/doi.org\/10.1007\/s12026-022-09267-y","journal-title":"Immunol Res"},{"key":"1566_CR144","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.bbrc.2018.06.072","volume":"503","author":"J Shou","year":"2018","unstructured":"Shou J, Cao J, Zhang S, Sun R, Zhao M, Chen K, Su SB, Yang J, Yang T (2018) SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice. Biochem Biophys Res Commun 503:757\u2013762. https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.072","journal-title":"Biochem Biophys Res Commun"},{"key":"1566_CR145","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202411037","volume":"136","author":"W Shuai","year":"2024","unstructured":"Shuai W, Yang P, Xiao H, Zhu Y, Bu F, Wang A, Sun Q, Wang G, Ouyang L (2024) Selective covalent inhibiting JNK3 by small molecules for Parkinson\u2019s diseases. Angew Chem Int Ed Engl 136:e202411037. https:\/\/doi.org\/10.1002\/anie.202411037","journal-title":"Angew Chem Int Ed Engl"},{"key":"1566_CR146","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Nery ES (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"1566_CR147","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","volume":"14","author":"J Singh","year":"2010","unstructured":"Singh J, Petter RC, Kluge AF (2010) Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 14:475\u2013480. https:\/\/doi.org\/10.1016\/j.cbpa.2010.06.168","journal-title":"Curr Opin Chem Biol"},{"key":"1566_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105414","volume":"167","author":"R Singh","year":"2021","unstructured":"Singh R, Kaundal RK, Zhao B, Bouchareb R, Lebeche D (2021) Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK\/STAT3 and JNK\/c-Jun signaling. Pharmacol Res 167:105414. https:\/\/doi.org\/10.1016\/j.phrs.2020.105414","journal-title":"Pharmacol Res"},{"key":"1566_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116792","volume":"482","author":"B Singh","year":"2024","unstructured":"Singh B, Patwardhan RS, Pal D, Maurya DK, Singh BG, Checker R, Sharma D, Sandur SK (2024) Repurposing of FDA approved kinase inhibitor bosutinib for mitigation of radiation induced damage via inhibition of JNK pathway. Toxicol Appl Pharmacol 482:116792. https:\/\/doi.org\/10.1016\/j.taap.2023.116792","journal-title":"Toxicol Appl Pharmacol"},{"key":"1566_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179207","volume":"22","author":"J Sinsky","year":"2021","unstructured":"Sinsky J, Pichlerova K, Hanes JJ (2021) Tau protein interaction partners and their roles in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 22:9207. https:\/\/doi.org\/10.3390\/ijms22179207","journal-title":"Int J Mol Sci"},{"key":"1566_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104032","volume":"29","author":"T Sobierajski","year":"2024","unstructured":"Sobierajski T, Ma\u0142olepsza J, Pichlak M, Gendaszewska-Darmach E, B\u0142a\u017cewska KM (2024) The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation. Drug Discov Today 29:104032. https:\/\/doi.org\/10.1016\/j.drudis.2024.104032","journal-title":"Drug Discov Today"},{"key":"1566_CR152","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/1535-7163.MCT-21-1044","volume":"21","author":"M Soleimani","year":"2022","unstructured":"Soleimani M, Somma A, Kaoud T, Goyal R, Bustamante J, Wylie DC, Holay N, Looney A, Giri U, Triplett T (2022) Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB-and TFE3-mediated lysosome biogenesis and autophagy. Mol Cancer Ther 21:1547\u20131560","journal-title":"Mol Cancer Ther"},{"key":"1566_CR153","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1310\/hpj4803-190","volume":"48","author":"DA Solimando Jr","year":"2013","unstructured":"Solimando DA Jr, Waddell J (2013) Drug monographs: bosutinib and regorafenib. Hosp Pharm 48:190\u2013194","journal-title":"Hosp Pharm"},{"key":"1566_CR154","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/bmj-2024-080952","volume":"14","author":"A Spinaci","year":"2025","unstructured":"Spinaci A, Buccioni M, Dal Ben D, Francucci B, Klotz K-N, Marucci G, Simola N, Morelli M, Pinna A, Volpini RJC (2025) A2A adenosine receptor antagonists and their efficacy in rat models of Parkinson\u2019s disease. Cells 14:338. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"Cells"},{"key":"1566_CR155","doi-asserted-by":"crossref","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JS, Zhang J, Yan R & Zheng X, JB (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. 388.","DOI":"10.1136\/bmj-2024-080952"},{"key":"1566_CR156","doi-asserted-by":"crossref","unstructured":"Sweet K, Pinilla-Ibarz J, Zhang L, JPP & Adherence (2014) Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. 981\u2013986.","DOI":"10.2147\/PPA.S53160"},{"key":"1566_CR157","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00535-012-0619-7","volume":"48","author":"A Szuster-Ciesielska","year":"2013","unstructured":"Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, Kandefer-Szersze\u0144 MJ (2013) Butein inhibits ethanol-induced activation of liver stellate cells through TGF-\u03b2, NF\u03baB, p38, and JNK signaling pathways and inhibition of oxidative stress. J Gastroenterol 48:222\u2013237","journal-title":"J Gastroenterol"},{"key":"1566_CR158","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1021\/acschemneuro.4c00339","volume":"15","author":"R Tenchov","year":"2024","unstructured":"Tenchov R, Sasso JM, Zhou Q (2024) Alzheimer\u2019s disease: exploring the landscape of cognitive decline. ACS Chem Neurosci 15:3800\u20133827. https:\/\/doi.org\/10.1021\/acschemneuro.4c00339","journal-title":"ACS Chem Neurosci"},{"key":"1566_CR159","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/acel.12473","volume":"15","author":"V Triaca","year":"2016","unstructured":"Triaca V, Sposato V, Bolasco G, Ciotti MT, Pelicci P, Bruni AC, Cupidi C, Maletta R, Feligioni M, Nistic\u00f2 R (2016) NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer\u2019s disease. Aging Cell 15:661\u2013672","journal-title":"Aging Cell"},{"key":"1566_CR160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"1566_CR161","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","volume":"32","author":"GE Vitek","year":"2023","unstructured":"Vitek GE, Decourt B, Sabbagh MN (2023) Lecanemab (BAN2401): an anti\u2013beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs 32:89\u201394. https:\/\/doi.org\/10.1080\/13543784.2023.2178414","journal-title":"Expert Opin Investig Drugs"},{"key":"1566_CR162","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pneurobio.2006.08.002","volume":"80","author":"V Waetzig","year":"2006","unstructured":"Waetzig V, Zhao Y, Herdegen T (2006) The bright side of JNKs\u2014multitalented mediators in neuronal sprouting, brain development and nerve fiber regeneration. Prog Neurobiol 80:84\u201397. https:\/\/doi.org\/10.1016\/j.pneurobio.2006.08.002","journal-title":"Prog Neurobiol"},{"key":"1566_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-175","volume":"9","author":"L-W Wang","year":"2012","unstructured":"Wang L-W, Tu Y-F, Huang C-C, Ho C-J, JJON (2012) JNK signaling is the shared pathway linking neuroinflammation, blood\u2013brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. J Neuroinflammation 9:175","journal-title":"J Neuroinflammation"},{"key":"1566_CR164","doi-asserted-by":"publisher","first-page":"1583616","DOI":"10.3389\/fimmu.2025.1583616","volume":"16","author":"W Wang","year":"2025","unstructured":"Wang W, Gao Y, Chen Y, Cheng M, Sang Y, Wei L, Dai R, Wang Y, Zhang L (2025) TGF-\u03b2 inhibitors: the future for prevention and treatment of liver fibrosis? Front Immunol 16:1583616","journal-title":"Front Immunol"},{"key":"1566_CR165","doi-asserted-by":"publisher","first-page":"e938826","DOI":"10.12659\/MSM.938826","volume":"29","author":"M Warpechowski","year":"2023","unstructured":"Warpechowski M, Warpechowski J, Kulczy\u0144ska-Przybik A, Mroczko B (2023) Biomarkers of activity-dependent plasticity and persistent enhancement of synaptic transmission in Alzheimer disease: a review of the current status. Med Sci Monit 29:e938826\u2013e938831. https:\/\/doi.org\/10.12659\/MSM.938826","journal-title":"Med Sci Monit"},{"key":"1566_CR166","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ceb.2007.02.001","volume":"19","author":"CR Weston","year":"2007","unstructured":"Weston CR, Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142\u2013149. https:\/\/doi.org\/10.1016\/j.ceb.2007.02.001","journal-title":"Curr Opin Cell Biol"},{"key":"1566_CR167","doi-asserted-by":"publisher","first-page":"25651","DOI":"10.1074\/jbc.M501926200","volume":"280","author":"EA Willoughby","year":"2005","unstructured":"Willoughby EA, Collins MK (2005) Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein \u03b2-arrestin2. J Biol Chem 280:25651\u201325658. https:\/\/doi.org\/10.1074\/jbc.M501926200","journal-title":"J Biol Chem"},{"key":"1566_CR168","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/14756366.2020.1720013","volume":"35","author":"Q Wu","year":"2020","unstructured":"Wu Q, Wu W, Jacevic V, Franca TC, Wang X, Kuca K (2020) Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. J Enzyme Inhib Med Chem 35:574\u2013583","journal-title":"J Enzyme Inhib Med Chem"},{"key":"1566_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19336918.2024.2316576","volume":"18","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhao Y, Guan Z, Esmaeili S, Xiao Z, Kuriakose D (2024) JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties. Cell Adh Migr 18:1\u201311. https:\/\/doi.org\/10.1080\/19336918.2024.2316576","journal-title":"Cell Adh Migr"},{"key":"1566_CR170","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00884","author":"VR Wydra","year":"2025","unstructured":"Wydra VR, Plank N, Zwirner S, Selig R, Rasch A, Masberg B, L\u00e4Mmerhofer M, Zender L, Koch P, Albrecht WJ (2025) A \u201cLigand First\u201d Approach toward Selective, Covalent JNK2\/3 Inhibitors. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00884","journal-title":"J Med Chem"},{"key":"1566_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.881042","volume":"13","author":"J Xiao","year":"2022","unstructured":"Xiao J, Lu H, Ma T, Ni X, Chang T, Liu M, Li N, Lu P, Ke C, Tian Q (2022) Worenine prevents solar ultraviolet-induced sunburn by inhibiting JNK2. Front Pharmacol 13:881042","journal-title":"Front Pharmacol"},{"key":"1566_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1526482","volume":"16","author":"K Xie","year":"2025","unstructured":"Xie K, Cao H, Ling S, Zhong J, Chen H, Chen P, Huang R (2025) Global, regional, and national burden of chronic kidney disease, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Front Endocrinol 16:1526482 (JFIE)","journal-title":"Front Endocrinol"},{"key":"1566_CR173","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1161\/CIRCRESAHA.117.312536","volume":"122","author":"J Yan","year":"2018","unstructured":"Yan J, Zhao W, Thomson JK, Gao X, Demarco DM, Carrillo E, Chen B, Wu X, Ginsburg KS, Bakhos M, JCR (2018) Stress signaling JNK2 crosstalk with CaMKII underlies enhanced atrial arrhythmogenesis. Circ Res 122:821\u2013835","journal-title":"Circ Res"},{"key":"1566_CR174","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/cdd.2011.124","volume":"19","author":"G Yang","year":"2012","unstructured":"Yang G, Liu Y, Yang K, Liu R, Zhu S, Coquinco A, Wen W, Kojic L, Jia W, Cynader M (2012) Isoform-specific palmitoylation of JNK regulates axonal development. Cell Death Differ 19:553\u2013561. https:\/\/doi.org\/10.1038\/cdd.2011.124","journal-title":"Cell Death Differ"},{"key":"1566_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.811584","volume":"12","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhou W, Xu X, Ge X, Wang F, Zhang G-Q, Miao L, Deng X (2022) Aprepitant inhibits JNK and p38\/MAPK to attenuate inflammation and suppresses inflammatory pain. Front Pharmacol 12:811584","journal-title":"Front Pharmacol"},{"key":"1566_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1533652","volume":"16","author":"P Yao","year":"2025","unstructured":"Yao P, Guo X, Guo Z, Lin W, Liu M, Chen M, Li J, Cui L-B, Lv D (2025) Clinical efficacy of modified suanzaoren decoction compared to esazolam tablets in the treatment of chronic insomnia disorder. Front Psychiatry 16:1533652","journal-title":"Front Psychiatry"},{"key":"1566_CR177","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.neuron.2012.06.024","volume":"75","author":"SO Yoon","year":"2012","unstructured":"Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, Lim TH, Pastorino L, Kunwar AJ, Walton JC (2012) JNK3 perpetuates metabolic stress induced by A\u03b2 peptides. Neuron 75:824\u2013837","journal-title":"Neuron"},{"key":"1566_CR178","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1128\/MMBR.00043-14","volume":"80","author":"A Zeke","year":"2016","unstructured":"Zeke A, Misheva M, Rem\u00e9nyi A, Bogoyevitch M (2016) JNK signaling: regulation and functions based on complex protein-protein partnerships. Microbiol Mol Biol Rev 80:793\u2013835. https:\/\/doi.org\/10.1128\/MMBR.00043-14","journal-title":"Microbiol Mol Biol Rev"},{"key":"1566_CR179","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","volume":"19","author":"T Zhang","year":"2012","unstructured":"Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T (2012) Discovery of potent and selective covalent inhibitors of JNK. Chem Biol 19:140\u2013154. https:\/\/doi.org\/10.1016\/j.chembiol.2011.11.010","journal-title":"Chem Biol"},{"key":"1566_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1273248","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang L, Chen Y, Fang X, Li B, Mo C (2023) The role of cGAS-STING signaling in pulmonary fibrosis and its therapeutic potential. Front Immunol 14:1273248. https:\/\/doi.org\/10.3389\/fimmu.2023.1273248","journal-title":"Front Immunol"},{"key":"1566_CR181","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","volume":"19","author":"X Zhao","year":"2020","unstructured":"Zhao X, Kwan JYY, Yip K, Liu PP, Liu F (2020) Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov 19:57\u201375. https:\/\/doi.org\/10.1038\/s41573-019-0040-5","journal-title":"Nat Rev Drug Discov"},{"key":"1566_CR182","doi-asserted-by":"publisher","first-page":"10013","DOI":"10.1021\/jm501256y","volume":"57","author":"K Zheng","year":"2014","unstructured":"Zheng K, Iqbal S, Hernandez P, Park H, Lograsso PV, Feng Y (2014) Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem 57:10013\u201310030. https:\/\/doi.org\/10.1021\/jm501256y","journal-title":"J Med Chem"},{"key":"1566_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.53","volume":"2","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Li S, Wang A, Zhe M, Yang P, Wu Y, Zhao M, Zhu Y, Luo Y, Wang G (2023) p38 mitogen-activated protein kinase: functions and targeted therapy in diseases. MedComm \u2013 Oncology 2:e53. https:\/\/doi.org\/10.1002\/mog2.53","journal-title":"MedComm \u2013 Oncology"},{"key":"1566_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114378","volume":"237","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, He X, Ge J, Zhu J, Yao C, Cai H, Ye X-Y, Xie T, Bai R (2022) Discovery of small-molecule compounds and natural products against Parkinson\u2019s disease: Pathological mechanism and structural modification. Eur J Med Chem 237:114378. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114378","journal-title":"Eur J Med Chem"},{"key":"1566_CR185","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1002\/ptr.8217","volume":"38","author":"M Zhu","year":"2024","unstructured":"Zhu M, Sun Y, Su Y, Guan W, Wang Y, Han J, Wang S, Yang B, Wang Q, Kuang H (2024) Luteolin: a promising multifunctional natural flavonoid for human diseases. Phytother Res 38:3417\u20133443. https:\/\/doi.org\/10.1002\/ptr.8217","journal-title":"Phytother Res"},{"key":"1566_CR186","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S395887","author":"Z Zulfiqar","year":"2020","unstructured":"Zulfiqar Z, Shah FA, Shafique S, Alattar A, Ali T, Alvi AM, Rashid S, Li S (2020) Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats [Retraction]. J Inflamm Res. https:\/\/doi.org\/10.2147\/JIR.S395887","journal-title":"J Inflamm Res"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01566-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:03:47Z","timestamp":1762322627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01566-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":186,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01566-w","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review paper does not involve any experimental research with human participants or animals performed by the authors. All data and information included in this study were sourced from previously published literature, databases, and publicly available resources, ensuring compliance with ethical guidelines. Proper citations have been provided for all referenced materials to acknowledge the contributions of original authors and avoid plagiarism. The authors affirm that this work complies with the ethical standards for academic publishing and adheres to the principles of integrity, transparency, and accountability in scientific communication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}